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Background: Chronic painful conditions have an important influence on the ability to work. Work-related outcomes,
however, are not commonly reported in publications on trials investigating the treatment of chronic painful conditions.
We aim to provide an overview of the reporting of work-related outcomes in such trials and investigate the relationship
between work-related outcomes and pain outcomes.
Methods: We conducted a systematic literature search in PubMed with the aim of identifying randomised
placebo-controlled clinical trials investigating treatments for chronic painful conditions or rheumatic diseases that
also reported on work-related outcomes. Methodological study quality was assessed with the Oxford Quality Scale
(OQS). Meta-analyses were conducted for the outcomes of interference with work and number of patients with at
least 30% reduction in pain intensity (30% pain responders). The correlation between work-related and pain
outcomes was investigated with regression analyses.
Results: We included 31 publications reporting on 27 datasets from randomised placebo-controlled trials
(with a total of 11,434 study participants) conducted in chronic painful or rheumatic diseases and reporting on
work-related outcomes. These 31 publications make up only about 0.2% of all publications on randomised
placebo-controlled trials in such conditions. The methodological quality of the included studies was high; only
nine studies scored less than four (out of a maximum five) points on the OQS. Sixteen different work-related
outcomes were reported on in the studies. Of 25 studies testing for the statistical significance of changes in
work-related outcomes over the course of the trials, 14 (56%) reported a significant improvement; the others
reported non-significant changes. Eight studies reported data on both interference with work and 30% pain
responders: meta-analyses demonstrated similar, statistically significant improvements in both these outcomes
with active therapy compared to placebo and regression analysis showed that these outcomes were correlated.
Conclusions: Despite the importance of pain as a reason for decreased ability to work, work-related outcomes are
reported in substantially less than 1% of publications on placebo-controlled trials in chronic painful and rheumatic
diseases. Work-related outcomes and pain responder outcomes are closely related.
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Chronic painful conditions are very common as a recent
systematic review of prevalence studies has demonstrated
[1]. For example, a large survey found that about one fifth
of European adults suffered from pain of at least six
months’ duration and a third of those pain sufferers had
severe pain [2]. Patients affected by a chronic painful dis-
ease experience the adverse effects of their condition on a
number of domains of life, including work. In different
studies 13% to 76% of chronic pain patients experienced
loss of employment or were unable to undertake employ-
ment [1]. Those with moderate and, especially, severe pain
are particularly affected [3]. Targeting inability to work
and interference with work due to chronic pain therefore
is important both from an individual as well as a societal,
economic, perspective. It would be informative to know
how work ability is affected by common pain treatments.
However, work-related outcomes are not commonly
reported in publications on randomised controlled trials
investigating the treatment of chronic painful conditions
or rheumatic diseases (where pain typically is a prominent
symptom). Where such data have been analysed, there is
good evidence that those patients experiencing substantial
improvements in pain outcomes in the context of clinical
trials also experience a substantial improvement in their
ability to work [4]. The question is how generalisable this
agreement between work-related and pain-related study
outcomes is.
With this publication we aim to, firstly, provide an over-
view of the reporting of work-related outcomes in chronic
pain trials and, secondly, investigate the relationship be-
tween work-related outcomes and pain-related outcomes
across different studies. Because for pain intensity the
reporting as ‘responder outcomes’ , such as the proportion
of study participants experiencing at least 30%, or 50%, re-
duction in pain intensity over the course of a trial (30% or
50% pain responders), is more informative than treatment
group average data, we focus on pain responder outcomes;
this is in agreement with recent guidance on performing
systematic reviews in the chronic pain field [5].Methods
Literature search, study quality assessment, and data
extraction
We conducted a systematic literature search in Medline
(PubMed) with the aim of identifying randomised con-
trolled clinical trials investigating treatments for chronic
painful conditions or rheumatic diseases that reported on
any work-related study outcomes. We limited ourselves to
placebo-controlled (or sham-controlled) studies to ensure
some basic comparability between the studies and to be
able to compare active treatments vs. placebo for work-
related and pain-related study outcomes.Our search strategy is shown in Figure 1 and included
search terms to identify work-related outcomes, search
terms to identify chronic painful conditions or rheum-
atic diseases, and search terms to identify placebo or
sham controlled studies. We did not activate any filters
in PubMed but limited ourselves to articles published as
full papers in English or German. The date of the last
search was 13 June 2013. To estimate the total number
of publications that could potentially have reported on
work-related outcomes, we also performed our search
without the work-related terms.
For inclusion in our systematic review studies needed
to be single or double blind, use a placebo or sham con-
trol, include patients suffering from chronic pain (of at
least 3 months’ duration) or with a rheumatic disease, and
report on any work-related outcomes. We anticipated that
a variety of work-related measures would be reported in
the studies. In order to be inclusive we accepted any out-
come measure that specifically addresses work or any as-
pect of work and were work-related effects were reported
separately (i.e. not only as a summary score covering work
and other domains of life). Studies investigating children
or experimentally induced pain were excluded.
We assessed the methodological study quality with the
Oxford Quality Scale, a standard and very widely used
instrument for evaluating clinical trials that assesses the
domains of randomisation, blinding and withdrawals/
dropouts, and grades study quality on a scale of zero to
five points [6].
Data were extracted on the publication details, the con-
ditions studied, the treatments investigated, study size and
duration, as well as work-related and pain-related study
outcomes.
Data analysis
We assessed means (and standard deviations [SDs]) of
differences in work-related outcomes between trial be-
ginning and end. If a study did not report SDs for mean
differences between baseline and end of study values,
SDs were estimated from p-values from hypothesis tests
on the baseline to trial end differences. Studies reporting
medians and interquartile ranges only had their data
transformed to means and SDs by assuming the median
to be the mean and the interquartile range to be 1.35
SDs.
Meta-analysis of data was performed with Review
Manager (RevMan) [7]. Meta-analyses were conducted
for the outcomes of ‘interference with work’ and 30% pain
responders. Data for ‘interference with work’ were from
component questions of the Brief Pain Inventory (ques-
tion on pain interfering with normal work, including both
work outside the home and housework), the Fibromyalgia
Impact Questionnaire (question on how much pain or
other symptoms of fibromyalgia interfered with the ability
work OR work* OR employ* OR employment OR job OR
job* OR labor OR labor* OR labour* OR
LWDE OR sick leave OR economic OR sick listed
AND
(chronic AND pain) OR (chronic AND pain*) OR chronic pelvic pain syndrome OR
back pain OR neck pain OR fibromyalgia OR chronic whiplash injury OR 
neuralgia OR complex regional pain syndrome OR
musculoskeletal OR osteoarthritis OR osteoarthrosis OR facet syndrome OR
spondylarthritis OR arthritis OR Reiter's syndrome OR gout OR 
polymyalgia rheumatica OR myalgia OR spondylitis OR granulomatosis OR 
polyarteritis OR polyangiitis OR joint OR joint* OR polymyositis OR 
connective tissue disease OR systemic lupus erythematosus OR
panarteritis nodosa OR periarteritis nodosa OR 






































Figure 1 Search strategy. LWDE – lost workday equivalents.
Wolf et al. Journal of Occupational Medicine and Toxicology 2014, 9:25 Page 3 of 10
http://www.occup-med.com/content/9/1/25to do work, including housework) and the Sheehan Dis-
ability Scale (question on how much the symptoms have
disrupted work or school work). These three questions
were all assessed on scales of 0–10 points.
For meta-analyses the random effects model was used.
If the between study heterogeneity was estimated to be
zero (i.e. I2 = 0), the analysis is equivalent to a fixed effect
meta-analysis.
The relationships between the outcomes of interference
with work and 30%, or 50%, pain responders were investi-
gated with regression analyses.
A further regression analysis was conducted for work-
related and pain-related outcomes expressed as mean dif-
ferences. In order to utilise all available data, which were
expressed as different outcomes, we standardised the mean
differences of the work-related and pain-related endpoints,as described by Hedges [8], before performing linear re-
gression analysis.
All regression analyses were conducted in R [9]. The
weights for the included studies were assigned according
to the inverse variances of their work-related endpoints.
Results
Reporting of work-related outcomes
Our systematic literature search (Figure 2) yielded 1063
potentially relevant hits of which 948 were excluded as
not relevant on the basis of study titles and abstracts. One
hundred and fifteen remaining articles and one additional
study from the references of a meta-analysis were exam-
ined as full texts. Eighty five of these full texts needed to
be excluded. Additional file 1 details the excluded studies
with reasons for their exclusion.
Systematic literature search (Medline)
1063 articles
Fulltext screening 







31 articles with 
work-related study outcomes
Figure 2 Study selection.
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review 31 publications [4,10-39] reporting on 27 datasets
from randomised placebo-controlled trials in chronic pain-
ful diseases or rheumatic diseases (Table 1). Typically such
a dataset corresponds to data from one clinical trial. Arnold
et al. [12] and Bradley et al. [18] are meta-analyses that in-
corporated the same four clinical trials [11,20,40,41]. Two
of these published work-related data [11,20]. In order to
avoid counting the same patients more than once, all
these studies were treated as one dataset. Bennett et al.
[16] and Bennett et al. [17] were also treated as one data-
set, because they both reported on the same trial. Further-
more, Straube et al. [4] reported an individual patient
meta-analysis of work-related data from four trials but
was counted as one dataset because the work-related data
had not been published separately for those trials.
The 31 publications reporting on work-related outcomes
comprised only 0.23% of all publications on randomised
placebo-controlled trials in chronic painful or rheumatic
conditions (13,754 hits when searching as in Figure 1 but
without the work-related search terms). The 31 studies
that reported on work-related outcomes included a total of
11,434 patients (mean ages in the studies ranged from 34to 63 years; overall 76% of patients were women). Among
the 31 studies, the reporting of work-related outcomes was
diverse: 16 different work-related outcomes were reported
on (Table 1). The methodological study quality was gener-
ally high; only nine studies scored less than four (out of a
maximum five) points on the OQS (Table 1).
Of 25 studies testing for the statistical significance of
changes in work-related outcomes over the course of the
trials, 14 (56%) reported a significant improvement; the
others reported non-significant changes (Table 2).
Relationship between work and pain outcomes
We wanted to examine the relationship between work-
related outcomes and pain-related outcomes. As elabo-
rated above we primarily used responder outcomes for
pain intensity and as regards work-related outcomes
we used the outcome of ‘interference with work’ as es-
timated from the answers to similar questions about
interference with work (or disruption of work) from
three commonly used questionnaires. There were eight
studies [4,12,21,22,32,34-36] that reported data on both
interference with work and 30% pain responders; these
studies were included in meta-analyses for the outcomes
Table 1 Details of the included studies
Data
sets
Articles Conditions Active interventions Patients Work-related outcomes Study duration
(in weeks)
OQS score
1 Albert et al. 2013 [10] Chr. back pain Amoxicillin–Clavulanate 162 Time lost from work 52 5
2 Baron et al. 2010 [14] Chr. back pain Pregabalin 217 WPAI 5 4
3 Carlsson & Sjölund 2001 [19] Chr. back pain Acupuncture, electroacupuncture 51 Employment status 32 5
4 Jarzem et al. 2005 [25] Chr. back pain TENS 350 McGill Work Scale 12 5
5 Lehmann et al. 1986 [29] Chr. back pain TENS, electroacupuncture 54 Employment status 3 4
6 Licciardone et al. 2003 [30] Chr. back pain Osteopathic manipulative treatment 91 Time lost from work 20 3
7 Skljarevski et al. 2009 [34] Chr. back pain Duloxetine 404 BPI-I 13 5
8 Skljarevski et al. 2010a [35] Chr. back pain Duloxetine 236 BPI-I, WPAI 13 4
9 Skljarevski et al. 2010b [36] Chr. back pain Duloxetine 401 BPI-I, WPAI 12 3
10 He et al. 2005 [24] Chr. neck pain Body acupuncture + body
electrostimulation + ear acupressure
24 Activity impairment at work 4 2
11 Manchikanti et al. 2010 [31] Chr. neck pain Bupivacaine and steroid injection 120 Employability, employment status 96 5
12 Bennett et al. 2003 + 2005 [16,17] Fibromyalgia Tramadol-Acetaminophen 315 FIQ, time lost from work, SF-36 8 3
13 Bradley et al. 2010 [18] + Arnold et al.
2009 [12] (Arnold et al. 2005
[11] + Chappell et al. 2008 [20])
Fibromyalgia Duloxetine 1332 Bradley 2010 [18]: FIQ, Arnold
2009 [12]: SDS (Arnold 2005 [11]:
BPI, Chappell 2008 [20]: SDS)
12-28 Review (Arnold et al. 2005 [11]:
5, Chappell et al. 2008 [20]: 3)
14 Straube et al. 2011 [4] Fibromyalgia Pregabalin 2757 FIQ, time lost from work, SF-36,
SDS, MAF
8-14 Review
15 Chappell et al. 2009 [21] Osteoarthritis
(knee)
Duloxetine 231 BPI-I 13 5
16 Chappell et al. 2011 [22] Osteoarthritis
(knee)
Duloxetine 256 BPI-I 13 5
17 Markenson et al. 2005 [32] Osteoarthritis Oxycodone 109 BPI-I 12 4
18 Kavanaugh et al. 2006 [26] Psoriatic
arthritis
Infliximab 200 SF-36, employment status,
employability, impact on
productivity at work (VAS), time
lost from work
22 3
19 Kavanaugh et al. 2013 [28] Psoriatic
arthritis
Golimumab 405 Impact on productivity at work
(VAS)
24 4
20 Egsmose et al. 1997 [23] Reactive
arthritis
Sulphasalazine 83 Time lost from work 24 3
21 Bejarano et al. 2008 [15] Rheumatoid
arthritis
Adalimumab +MTX 148 Employment status, WIS, Time
lost from work
56 5
22 Kavanaugh et al. 2009 [27] Rheumatoid
arthritis
Certolizumab pegol + MTX 1601 WPS, time lost from work 24 + 52 3
23 Meireles et al. 2010 [33] Rheumatoid
arthritis





















Table 1 Details of the included studies (Continued)
24 Smolen et al. 2006 [37] Rheumatoid
arthritis
Infliximab +MTX 1004 Employability, time lost from work 54 5
25 Strand et al. 1999 [38] Rheumatoid
arthritis
Leflunomide, MTX 482 Productivity at work 48 4
26 Barkham et al. 2010 [13] Ankylosing
spondylitis
Entanercept 40 WIS, time lost from work 12 3
27 van der Heijde et al. 2006 [39] Ankylosing
spondylitis
Infliximab 279 SF-36, impact on productivity at
work (VAS), time lost from work
24 4
BPI-I – Brief Pain Inventory: Interference with normal work; chr. – chronic; DASH – Disabilities of the Arm, Shoulder and Hand Questionnaire; FIQ – Fibromyalgia Impact Questionnaire; MAF – Multidimensional
Assessment of Fatigue; MTX – methotrexate; OQS – Oxford Quality Scale; SDS – Sheehan Disability Scale; SF-36 – Short Form 36 Health Survey; TENS – transcutaneous electrical nerve stimulation; VAS – visual analogue
scale; WIS – Work Instability Scale; WPAI – Work Productivity and Activity Impairment Questionnaire; WPS – Work Productivity Survey. For reviews, information in brackets refers to the primary publications on





















Table 2 ‘Vote count’ of studies investigating work-related
outcomes with statistical methods
Significant improvement Non-significant changes
Bejarano et al. 2008 [15] Albert et al. 2013 [10]
Bennett et al. 2003 [16] Barkham et al. 2010 [13]
Bradley et al. 2010 [18] Baron et al. 2010 [14]
Chappell et al. 2011 [22] Chappell et al. 2009 [21]
He et al. 2005 [24] Egsmose et al. 1997 [23]
Kavanaugh et al. 2006 [26] Jarzem et al. 2005 [25]
Kavanaugh et al. 2009 [27] Lehmann et al. 1986 [29]
Kavanaugh et al. 2013 [28] Licciardone et al. 2003 [30]
Meireles et al. 2010 [33] Skljarevski et al. 2009 [34]
Markenson et al. 2005 [32] Straube et al. 2011 [4]
Skljarevski et al. 2010a [35] van der Heijde et al. 2006 [39]
Skljarevski et al. 2010b [36]
Smolen et al. 2006 [37]
Strand et al. 1999 [38]
The results of active treatment groups were pooled. Studies reported either
significant improvements or non-significant changes; no study reported a
significant worsening in work-related outcomes.
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sponders (Figure 4). For Straube et al. [4] data about
pain responders was taken from Straube et al. [42].
These meta-analyses demonstrated statistically signifi-
cant improvements in both outcomes with active therapy
compared to placebo and also demonstrated that both
outcomes behaved in a roughly similar manner, in individ-
ual studies and overall.
To assess the degree of similarity between these outcomes
formally, we performed regression analyses (Figure 5);
these showed that the outcomes were significantly cor-
related when the 30% responder rates were expressed as
risk differences (p = 0.012) as well as when they were
expressed as risk ratios (p = 0.015). For the 50% responder
rates we found a significant correlation when the re-
sponder rates were expressed as risk ratios (p = 0.038), butFigure 3 Interference with work. Meta-analysis of the improvement in in
interval, Fixed – fixed effect model, IV – inverse variance, SD – standard designificance was narrowly missed when they were expressed
as risk differences (p = 0.053). As the study of Skljarevski
et al. [34] did not report 50% pain responder rates, it did
not contribute to those analyses.
Nine studies reported mean differences of different
pain-related and work-related outcomes. Six trials assessed
interference with work and pain severity with questions
from the Brief Pain Inventory [21,22,32,34-36]. Arnold
et al. [12] reported data on disruption of work from the
Sheehan Disability Scale and data on pain from the Brief
Pain Inventory. Two studies used visual analogue scales
to evaluate productivity at work and pain [26,39]. The
data for the pain-related outcomes for these two studies,
Kavanaugh et al. [26] and van der Heijde et al. [39], were
taken from Antoni et al. [43] and van der Heijde et al.
[44]. Because of the multiple outcomes reported across
the papers we standardised the reported mean differences
before performing linear regression. Again, a statistically
significant correlation emerged (p = 0.035).Discussion
We were able to confirm our impression that work-related
outcomes are indeed reported only very infrequently in
chronic pain and rheumatology trials. This is somewhat
surprising, given the importance of pain as a reason for
decreased ability to work and given that a number of
questionnaires that are commonly used in pain and
rheumatology trials contain component questions ad-
dressing work-related outcomes [4]. The problem very
likely is not one of the collection of work-related data
but of the reporting of such data in publications.
This means two things. Firstly, that raising awareness of
the importance of work-related outcomes among people
and institutions involved in conducting trials in chronic
pain and rheumatology is worthwhile and may lead to
such data being reported more commonly for future trials
and, secondly, that re-analysis of existing datasets could
be informative, as long as access to work-related data canterference with work over the duration of the studies. CI – confidence
viation.
Figure 4 30% pain responders. Meta-analysis of the proportion of study participants attaining at least 30% reduction in pain intensity over the
duration of the studies. CI – confidence interval, IV – inverse variance, Random – random effects model, SD – standard deviation.
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patient.
Some limitations of our analysis need to be discussed:
we based our systematic review on searching only one
database and were limited (due to the linguistic skills of
the authors, or lack thereof) to papers published in English
or German. It is quite possible that we missed relevant
studies published in journals not indexed in Medline,
published in languages other than English or German, or
published after our search had closed. We do not claim,
therefore, to have identified all placebo-controlled trials
conducted in chronic pain or rheumatologic diseases and
reporting on work related outcomes. What we have, how-
ever, should be a fairly good and representative sample,Figure 5 Regression analysis. Regression analysis of the improvement in
responders’, expressed as risk ratios [RR, red colour] or risk differences [RD,
points. The size of the symbols represents the weights of the individual stu
solid; broken lines mark the 95% confidence intervals.including important trials published recently and in high
impact journals.
We have confidence in our conclusion, therefore, that
work-related outcomes are indeed reported very infre-
quently in journal publications resulting from chronic
pain and rheumatology trials.
Chronic pain significantly interferes with work. A recent
large systematic review of observational studies demon-
strated the negative impact of chronic pain on work re-
lated outcomes [45]. It is therefore logical to suspect that
pain relief will be associated with an improvement in the
ability to work. Based on the evidence included in our
systematic review (eight studies, with 5726 participants,
conducted in fibromyalgia, back pain and osteoarthritis,interference with work from study beginning to end and ‘30% pain
blue colour]. Interference with work was measured on a scale of 0–10
dies in the regression analysis (inverse variance). Regression lines are
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oxicodone, and lasting eight to 28 weeks) we conclude
that the outcome of improvement in interference with
work is indeed closely related to the outcome of attain-
ing at least 30% reduction in pain intensity over the
course of the studies. Future work, in other painful con-
ditions and assessing different treatments, needs to as-
sess how robust this relationship is and whether pain-
related outcomes (such as 30% pain responders) can
perhaps be used to estimate interference with work. If
they can, then this would open the door to using pain
responder outcomes for evaluations of the impact of
pain treatments also on work ability, which might be an
important consideration for the assessment of pain
treatments.
Conclusions
Firstly, work-related outcomes are reported very infre-
quently, in substantially less than 1% of the publications
we identified in our search for placebo-controlled trials in
chronic painful and rheumatic diseases.
Secondly, work-related outcomes and pain responder
outcomes are closely related. Future studies, perhaps based
on individual patient analyses and meta-analyses of exist-
ing datasets, should address whether pain responder out-
comes can be used to assess ability to work.
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